Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells 14,569 Shares of Stock

Key Points

• Major shareholder Bioventures 2014 L.P. Mpm sold 14,569 Entrada Therapeutics shares at an average price of $7.06, generating $102,857.14. The sale reduced its direct ownership by 0.34% to 4.32 million shares.
• The shareholder also sold 48,145 shares over the prior two trading days, bringing its recent three-day sales total to 62,714 shares.
• Entrada shares closed at $7.00, near their 50-day average of $7.08 and well below the 52-week high of $16.45. The company missed its latest earnings and revenue estimates, although analysts maintain a consensus “Moderate Buy” rating with a $17.75 price target.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the firm's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the transaction, the insider directly owned 4,318,348 shares in the company, valued at $30,487,536.88. The trade was a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Tuesday, August 25th, Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88.
• On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.34, for a total transaction of $158,712.82.

Entrada Therapeutics Stock Performance

NASDAQ:TRDA traded down $0.62 on Wednesday, hitting $7.00. The stock had a trading volume of 229,319 shares, compared to its average volume of 334,500. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45. The firm's fifty day simple moving average is $7.08 and its two-hundred day simple moving average is $9.36. The stock has a market cap of $272.58 million, a P/E ratio of -1.77 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million during the quarter, compared to analysts' expectations of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. Equities research analysts predict that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Large investors have recently modified their holdings of the stock. Odyssean LLC purchased a new stake in shares of Entrada Therapeutics during the 2nd quarter worth approximately $230,000. Nantahala Capital Management LLC purchased a new position in Entrada Therapeutics in the second quarter valued at approximately $2,212,232,000. Public Employees Retirement System of Ohio purchased a new position in Entrada Therapeutics in the second quarter valued at approximately $276,000. Bank of America Corp DE bought a new position in Entrada Therapeutics during the second quarter valued at $426,000. Finally, 5AM Venture Management LLC bought a new position in Entrada Therapeutics during the second quarter valued at $29,854,949,000. Hedge funds and other institutional investors own 86.39% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Roth Capital reissued a "buy" rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a research report on Monday, June 8th. Weiss Ratings cut Entrada Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 13th. Finally, HC Wainwright downgraded shares of Entrada Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, May 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Entrada Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.75.

About Entrada Therapeutics

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source